All In Biotech

Drug Trial Radar · NCT07416539

Effect of COV2 Vaccine Formulation on the Ability to Generate Antibodies Against Coronavirus That Causes COVID-19

A Phase 1a, Single-Blind, Randomized Comparative Clinical Trial Evaluating the Impact of Vaccine Formulation on the Safety and Immunogenicity of the COV2 Vaccine in Healthy Adults

Last checked: Nov 20, 2026Latest source record: Jul 22, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

20

Planned (sponsor's estimate)

Start

Feb 10, 2026

Primary completion

Nov 2026

Study completion Nov 2026

Sponsor

Lead sponsor
Rokote Laboratories Finland OyIndustry
Sponsor type
Industry
Collaborators
Oy Medfiles Ltd; Estimates OY
First posted
Feb 18, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Parallel
Masking
Single (participant)
Primary purpose
Prevention
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This is a Phase 1a, single-country, single-centre, single-blinded, COV2 vaccine formulation randomized trial designed to investigate and compare the safety and immunogenicity of two COV2 vaccine formulations. COV2 is a nasal, investigational vaccine against COVID-19, based on a serotype 5 adenoviral vector producing modified SARS-CoV-2 spike protein. Participants will receive one of the two COV2 formulations in two doses on Day 0 and Day 28. This trial consists of two parts; Part 1 is a vaccination phase assessing safety and immunogenicity and Part 2 is a long-term immunogenicity follow-up assessing persistence of immune response.

Conditions

  • COVID - 19
  • SARS CoV-2

Interventions

  • COVID-19 VaccinesBiological

    COV2 vaccine given in formulation A in 2 doses as a nasal spray, 28 days between each dose.

  • COVID-19 VaccinesBiological

    COV2 vaccine given in formulation B in 2 doses as a nasal spray, 28 days between each dose.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Primary safety endpointsTime frame: From Day 0 to day 56
  2. Primary immunogenicity endpointTime frame: Day 56 from baseline

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Kuopio University Hospital, ENT policlinic

    Kuopio, Northern Savonia, Finland

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.